News

Amgevita is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic

Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares.  Additional future payments may be made

Bavencio, which is developed for intravenous use, has been approved to treat adults and pediatric patients aged 12 years and older with mMCC. Bavencio is a human programmed

The patent case against Biogen for Tecfidera was filed last year by Coalition for Affordable Drugs led by hedge fund manager Kyle Bass. Following the patent board’s ruling,

Akashi plans to initiate a new study, HALO-DMD-04. “We are pleased to learn that the FDA is allowing Akashi to resume the clinical development of HT-100,” said Pat

The initiative will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.

The RELAX-AHF-2 trial demonstrated that serelaxin did not achieve its primary endpoints of reduction in cardiovascular death through day 180 or reduced declining heart failure through day five when

As a newly established bioscience company in the immuno-oncology field and spin out from the French Atomic Energy Commission, H-Immune has developed a proprietary In Vitro Immunization (IVI)

Under the terms of the agreement X-Chem will apply its proprietary DEXTM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against